OBJECTIVES: Homeless adults have an increased risk of infectious diseases due to sexual and drug-related behaviors and substandard living conditions. We investigated the prevalence and risk factors for presence of hepatitis A virus (HAV) antibodies among homeless and marginally housed adults. METHODS: We analyzed serologic and questionnaire data from a study of marginally housed and homeless adults in San Francisco from April 1999 to March 2000. We tested seroprevalance for total antibodies to HAV (anti-HAV) and analyzed data using Chi-square tests and logistic regression. RESULTS: Of the 1,138 adults in the study, 52% were anti-HAV positive. The anti-HAV prevalence in this study population was 58% higher than the expected prevalence based on age-specific prevalence rates from the general population. Number of years of homelessness (< or =1, 2-4, and > or =5 years) was associated with anti-HAV prevalence (46%, 50%, and 61%, respectively, p < 0.001). We found other differences in anti-HAV prevalence (p < 0.05) for ever having injected drugs (63% vs. 42% for non-injectors), being foreign-born (75% vs. 51% among U.S.-born), race/ethnicity (72%, 53%, and 45% for Hispanic, white, and black people, respectively), and increasing age (38%, 49%, and 62% among those aged <35, 35-45, and >45 years, respectively). These variables all remained significant in a multivariate model. CONCLUSIONS: We found overall anti-HAV prevalence elevated in this San Francisco homeless population compared with the general U.S. population. These data show that anti-HAV was associated with homelessness independent of other known risk factors, such as being foreign-born, race/ethnicity, and injection drug use. This increase indicates an excess risk of HAV infection and the potential need to offer hepatitis A vaccination as part of homeless services.
OBJECTIVES: Homeless adults have an increased risk of infectious diseases due to sexual and drug-related behaviors and substandard living conditions. We investigated the prevalence and risk factors for presence of hepatitis A virus (HAV) antibodies among homeless and marginally housed adults. METHODS: We analyzed serologic and questionnaire data from a study of marginally housed and homeless adults in San Francisco from April 1999 to March 2000. We tested seroprevalance for total antibodies to HAV (anti-HAV) and analyzed data using Chi-square tests and logistic regression. RESULTS: Of the 1,138 adults in the study, 52% were anti-HAV positive. The anti-HAV prevalence in this study population was 58% higher than the expected prevalence based on age-specific prevalence rates from the general population. Number of years of homelessness (< or =1, 2-4, and > or =5 years) was associated with anti-HAV prevalence (46%, 50%, and 61%, respectively, p < 0.001). We found other differences in anti-HAV prevalence (p < 0.05) for ever having injected drugs (63% vs. 42% for non-injectors), being foreign-born (75% vs. 51% among U.S.-born), race/ethnicity (72%, 53%, and 45% for Hispanic, white, and black people, respectively), and increasing age (38%, 49%, and 62% among those aged <35, 35-45, and >45 years, respectively). These variables all remained significant in a multivariate model. CONCLUSIONS: We found overall anti-HAV prevalence elevated in this San Francisco homeless population compared with the general U.S. population. These data show that anti-HAV was associated with homelessness independent of other known risk factors, such as being foreign-born, race/ethnicity, and injection drug use. This increase indicates an excess risk of HAV infection and the potential need to offer hepatitis A vaccination as part of homeless services.
Authors: Beth P Bell; Deanna Kruszon-Moran; Craig N Shapiro; Stephen B Lambert; Geraldine M McQuillan; Harold S Margolis Journal: Vaccine Date: 2005-12-30 Impact factor: 3.641
Authors: Margot B Kushel; Judith A Hahn; Jennifer L Evans; David R Bangsberg; Andrew R Moss Journal: Am J Public Health Date: 2005-10 Impact factor: 9.308
Authors: S Vento; T Garofano; C Renzini; F Cainelli; F Casali; G Ghironzi; T Ferraro; E Concia Journal: N Engl J Med Date: 1998-01-29 Impact factor: 91.245
Authors: Naveed A Syed; Stephen D Hearing; Ian S Shaw; Christopher S Probert; Trevor N Brooklyn; E Owen Caul; Ralph E Barry; Joyshri Sarangi Journal: Eur J Gastroenterol Hepatol Date: 2003-08 Impact factor: 2.566
Authors: Emmanuelle A Dankwa; Christl A Donnelly; Andrew F Brouwer; Rui Zhao; Martha P Montgomery; Mark K Weng; Natasha K Martin Journal: Vaccine Date: 2021-10-20 Impact factor: 4.169
Authors: Sandra E Larios; Carmen L Masson; Michael S Shopshire; Jennifer Hettema; Ashly E Jordan; Courtney McKnight; Christopher Young; Mandana Khalili; Randy M Seewald; Albert Min; Nicholas Hengl; James L Sorensen; Don C Des Jarlais; David C Perlman Journal: J Subst Abuse Treat Date: 2013-11-11